China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
China Resources Boya Bio pharmaceutical Group Co Ltd
Cost of Revenue
China Resources Boya Bio pharmaceutical Group Co Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
|
Cost of Revenue
-¥991.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-23%
|
|
Beigene Ltd
HKEX:6160
|
Cost of Revenue
-¥2.7B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cost of Revenue
-¥1.1B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cost of Revenue
-¥992.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cost of Revenue
-¥39.6B
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
-63%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cost of Revenue
-¥99.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
See Also
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Cost of Revenue?
Cost of Revenue
-991.7m
CNY
Based on the financial report for Mar 31, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Cost of Revenue amounts to -991.7m CNY.
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-23%
Over the last year, the Cost of Revenue growth was 29%. The average annual Cost of Revenue growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been 8% over the past three years , and -23% over the past ten years .